Avanos Among Winners of FDA's Opioid Innovation Challenge
Thursday, December 20, 2018 12:25 PM

ALPHARETTA, Ga.Dec. 10, 2018 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) is pleased to announce it has been selected as one of eight winners of the FDA's Opioid Addiction Innovation Challenge. The product selected is an enhanced nerve visualization system in development by Avanos' Acute Pain division.   

The FDA launched the challenge in May 2018 to spur the development of medical devices and solutions to help combat the growing epidemic of opioid misuse and abuse. Avanos was selected as one of eight winners among more than 250 submissions from medical device companies and/or developers. 

"The opioid epidemic is one of the most severe health crises we face today, and we are committed to being part of the solution," said Joe Woody, Avanos chief executive officer. "Our selection is an exciting recognition of our focus on innovation and demonstrates that our increased R&D investment and capability is being recognized."  

Read more...
 
BIO Applauds Bipartisan 2018 Farm Bill
Monday, December 17, 2018 12:17 PM

WASHINGTON--(BUSINESS WIRE)--Biotechnology Innovation Organization (BIO) President & CEO James C. Greenwood today issued the following statement on the 2018 Farm Bill:

"BIO applauds the Farm Bill Conference Committee, led by Senators Pat Roberts (R-KS) and Debbie Stabenow (D-MI) and representatives Michael Conaway (R-TX) and Collin Peterson (D-MN), on coming to a long-term agreement on a 2018 Farm Bill. At a time of uncertainty for our nation’s farmers, the agricultural economy, and rural America, this bipartisan Farm Bill will provide the much-needed confidence and certainty for many Americans who rely on its programs and funding.

“As a result of BIO’s advocacy, the conference committee provided mandatory funding for key programs in the Farm Bill’s energy title. While BIO would have preferred the conference committee adopted the Senate-passed funding levels for the title, we applaud the conferees for understanding the importance of these programs and thank them for providing mandatory funding to allow these programs to continue. As I testified to Congress when work first began on this important legislation, the Farm Bill’s energy title programs are critical to our nation’s farmers and rural communities as they develop new renewable chemicals, bio-based products, advanced biofuels, and other products of industrial biotechnology.

Read more...
 
AdvaMed Statement on Medical Device Tax Moratorium
Tuesday, December 11, 2018 02:09 PM

Washington, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker as the House Ways and Means Committee released legislation that includes an extension of the moratorium on the medical device tax for an additional 5 years:

“The medical device excise tax is bad health policy and bad economic policy. No one disagrees on these points. We applaud the Committee for including a 5-year extension of the moratorium on the tax in its new extenders package, and we thank congressional medtech champions Rep. Erik Paulsen, Rep. Jackie Walorski, and Chairman Kevin Brady for spearheading this piece of the bill.

“A 5-year moratorium will give companies greater confidence in planning long-term R&D—a component that is critical to maintaining the longevity of the industry and sustaining the innovation ecosystem. Future breakthroughs in patient care are undermined by the threat of the medical device tax.

Read more...
 
MiMedx Announces Organizational Realignment Program
Friday, December 07, 2018 10:57 AM
Plan Will Improve Cost Structure and is Designed to Position Business for Long-Term Success

MARIETTA, Ga., Dec. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced its plans to implement a broad-based organizational realignment, cost reduction and efficiency program to better ensure the Company's cost structure is appropriate given its revenue expectations. MiMedx plans to execute these initiatives while continuing to deliver products and support for healthcare providers and the patients they serve. 

"Today's announcement is a continuation of management's efforts to position the business for long-term success by focusing on our wound care business, where our clinical studies best support patient outcomes and for which reimbursement policy has traditionally been more stable," said David Coles, Interim Chief Executive Officer. "Recent business trends and our internal analysis have led us to simplify and streamline our organizational structure, and reduce costs in order to improve profitability and liquidity."

The Company remains dedicated to executing its long-term strategic plan. In the near term, this includes a sharp focus on its traditional wound care business, further developing the Company's product pipeline, and continuing to pursue FDA approval for micronized dehydrated human amnion/chorion membrane (dHACM) to treat certain musculoskeletal pain indications as MiMedx transitions to a biopharmaceutical company. 

Read more...
 
AdvaMed Statement on ICIJ Medical Device Stories
Monday, November 26, 2018 10:14 AM

Washington, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement on the recent stories from the International Consortium of Investigative Journalists (ICIJ) on the medical technology industry:  

“Every one of us will inevitably face a moment where we will hope for a miracle to make a child, sibling, parent, grandparent or loved one well again. Whether it’s a pacemaker that keeps a heart beating, an implant that allows a child to hear for the first time, or an artificial knee that allows a grandmother to play with her grandkids, medical devices are the foundation of modern medicine, providing physicians and nurses the tools they rely on to improve patient care.       

“Yet, instead of a comprehensive look at both the challenges and the achievements of an industry that touches almost every human life, these stories counterfeit the life-changing and life-saving solutions delivered to billions of people worldwide.  

Read more...
 
<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 2 of 37